Table 2.
Medication Before Admission, Treatment Modality, Coronary Anatomy, Left Ventricular Systolic Function
| Variable | HbA1c ≤ 7.0% n = 178 | HbA1c > 7.0% n = 139 | P value |
|---|---|---|---|
| Medication before admission | |||
| Aspirin before admission, n (%) | 99 (55.62%) | 60 (43.17%) | 0.028 |
| Clopidigrel before admission, (n%) | 4 (2.25%) | 6 (4.31%) | NS |
| Statin, n(%) | 73 (41.01) | 46 (33.09) | NS |
| Anti‐diabetic therapy, n (%) | 112 (62.92%) | 95 (68.35%) | NS |
| Beta‐blocker, n (%) | 82 (46.07%) | 51 (36.69%) | NS |
| Angiotensin converting enzyme inhibitor, n(%) | 77 (43.26%) | 54 (38.85%) | NS |
| Angiotensin II receptor antagonist, n (%) | 9 (5.06%) | 12 (8.63%) | NS |
| Treatment Modality | |||
| Convervative, n (%) | 71 (39.89%) | 54 (38.85%) | NS |
| PCI, n (%) | 103 (57.87%) | 81 (58.27%) | NS |
| CABG, n (%) | 4 (2.24%) 4 (2.88%) | NS | |
| Coronary Anatomy | |||
| LMS Disease, n (%) | 11 (6.18%) | 8 (5.76%) | NS |
| One vessel disease, n (%) | 40 (22.47%) | 24 (17.27%) | NS |
| Two vessel disease, n (%) | 32 (17.98%) | 25 (17.99%) | NS |
| Three vessel disease, n (%) | 24 (13.48%) | 28 (20.14%) | NS |
| Left Ventricular Systolic Function | |||
| Ejection Fraction, (%) mean ± SD | 50.32% ± 14.48 | 50.32% ± 16.47 | NS |
Abbreviations: CABG, coronary artery bypass grafting; HbA1c, glycated hemoglobin; LMS, left main stem; NS, not significant; PCI, percutaneous coronary intervention; SD, standard deviation.